drugset / Trial / NCT00231777

A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)

NCT00231777

Phase 3 Completed 216 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

A new intravenous medication is being tested for the prevention of the nausea and vomiting that occurs after surgery. This new medication is being compared to another intravenous medication that is already available to patients for this indication.

Timeline

Start
2005-07
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ondansetron Other / unclassified 4 mg Intravenous
Subject fosaprepitant dimeglumine Unknown 40 mg Intravenous

Indications

No indication recorded.